Bispecific antibodies (bsAbs) can simultaneously bind to two separate and unique epitopes on the same or different antigens, sparking intense interest among the scientific community in recent years. Their dual specificity for soluble antigens has been explored extensively for various therapeutic applications, including cancer therapies and virus neutralization.
Creative Biolabs has invited Dr Archana Thakur and Dr Luca Varani to walk delegates through how they utilise the power of bsAbs to 1) arm "headless CAR T cells" and serially kill tumor targets and 2) neutralise wild-type SARS-CoV-2 and its variants and suppress viral escape.
Book your free place on the event website
and direct queries to Bella Smith at email@example.com